
AstraZeneca Pharma India surrenders marketing authorisation of prostate cancer drug
New Delhi: AstraZeneca Pharma India Ltd on Tuesday said it has surrendered the marketing authorisation of prostate cancer treatment drug Olaparib (Lynparza) 100mg and 150mg in India citing commercial reasons. The company had received marketing …